Welcome to our dedicated page for Biogen SEC filings (Ticker: BIIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biogen’s neuroscience pipeline stretches from multiple-sclerosis blockbusters to cutting-edge Alzheimer’s candidates, and the disclosures that follow are equally dense. If you’ve tried to spot pipeline milestones, patent cliffs, or R&D spend buried inside a 200-page filing, you know the challenge. Stock Titan turns that complexity into clarity by delivering Biogen SEC filings explained simply, in real time.
Our AI-powered summaries break down each Biogen annual report 10-K simplified, flagging segment revenue, drug concentration risk, and collaboration economics. Dig into a Biogen quarterly earnings report 10-Q filing without paging through footnotes—the platform highlights inventory swings, clinical-trial costs, and cash burn in seconds. Material updates like FDA decisions arrive as Biogen 8-K material events explained, so you never miss a catalyst.
The dashboard also tracks Biogen insider trading Form 4 transactions. Receive Biogen Form 4 insider transactions real-time to monitor Biogen executive stock transactions Form 4 before market open. Curious about leadership pay? The Biogen proxy statement executive compensation section is distilled into an easy-to-scan table. Whether you’re stress-testing valuation models or searching “How to read Biogen’s 10-K annual report?”, our AI delivers Biogen earnings report filing analysis that answers what professionals actually ask.
- Set keyword alerts for Leqembi, Spinraza, or biosimilar launches
- Compare quarter-over-quarter R&D trends instantly
- Export footnote-level data for financial models
Start understanding Biogen SEC documents with AI and spend minutes—not hours—finding what drives BIIB.
Biogen Inc. (BIIB) reported insider equity activity by its Head of Research. On 10/31/2025, 695 shares of common stock were acquired at $0 under a transaction coded M, reflecting settlement of previously granted RSUs. A separate transaction coded F covered 337 shares at $154.27. Following these transactions, the officer directly owned 1,791 shares of common stock.
The derivative table shows 695 restricted stock units outstanding after the activity, tied to an award granted on 11/01/2023 that vests in three equal annual installments beginning on 11/01/2024, with an expiration date of 11/01/2026.
Biogen Inc. reported Q3 2025 results in its 10-Q. Total revenue was $2,534.7 million, led by product revenue of $1,846.9 million, anti‑CD20 therapeutic programs of $493.9 million, Alzheimer’s collaboration revenue of $42.7 million, and contract manufacturing, royalty and other revenue of $151.2 million.
Operating lines showed cost of sales of $674.4 million, R&D of $436.1 million, and SG&A of $594.8 million. Net income was $466.5 million, with diluted EPS of $3.17. Comprehensive income reached $489.8 million.
On the balance sheet, cash and cash equivalents were $3,862.8 million, total assets $29,207.5 million, and notes payable $6,285.1 million. Year‑to‑date, operating cash flow was $1,692.7 million, investing cash flow $(139.4) million, and financing cash flow $(164.9) million. Shares outstanding were 146,702,272 as of October 28, 2025.
Biogen Inc. (BIIB) furnished third-quarter results. The company submitted a press release announcing results of operations and financial condition for the quarter ended September 30, 2025, furnished as Exhibit 99.1.
The press release was provided under Item 2.02 and is not deemed “filed” under Section 18 of the Exchange Act. Biogen’s common stock trades on the Nasdaq Global Select Market under the symbol BIIB.
Biogen Inc. announced a preliminary estimate for the quarter ended September 30, 2025: it expects approximately $2 million of acquired in‑process research and development, upfront and milestone expense. The company estimates this will reduce GAAP and non‑GAAP net income per diluted share for Q3 2025 by about ($0.01) per share.
Biogen began presenting this expense as a separate line item starting in the first quarter of 2025 to reflect costs tied to collaboration and license agreements, including upfront and milestone payments and, when applicable, premiums on equity securities and asset acquisitions of in‑process R&D. Results for the quarter have not been finalized and remain subject to financial statement closing procedures.
Sean Godbout, identified as a Director and the issuer's Chief Accounting Officer, reported changes in his beneficial ownership of BioGen Inc. (BIIB) on
Priya Singhal, Head of Development at Biogen Inc. (BIIB), reported a series of equity transactions dated 08/29/2025 and 09/02/2025. A grant of 1,669 restricted stock units (RSUs) vested (recorded as an acquisition at $0) increasing her beneficial ownership before sales to 7,096.1428 shares. On 08/29/2025 she sold 807 shares at $132.22 and on 09/02/2025 she sold 517 shares at $133.55, leaving her with 5,772.1428 shares following the reported transactions. The filing notes the RSU award was granted on September 1, 2022 and vests in three equal annual installments.
Biogen Inc. (BIIB) has filed a Form 144 notifying a proposed sale of 517 shares of common stock through Fidelity Brokerage Services. The filing lists an aggregate market value of $69,045.35 for the shares and states an approximate sale date of 09/02/2025 on NASDAQ. The shares were acquired on 09/01/2025 by restricted stock vesting from the issuer and payment is listed as compensation.
The filing shows 146,614,598 shares outstanding for the issuer. No securities sold in the past three months are reported and the filer represents there is no undisclosed material adverse information. The notice identifies Fidelity Brokerage Services LLC as the broker and includes the standard certification and signature/representation language required by Rule 144.
FAQ
What is the current stock price of Biogen (BIIB)?
What is the market cap of Biogen (BIIB)?
